Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Modified regimen of ublituximab in relapsing multiple sclerosis
2024-519284-18-00Phase 3Authorised
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3 trial of ublituximab in multiple sclerosis (MS) (3 arms), sponsored by TG Therapeutics, Inc. Primary endpoints: Part A primary: No change or reduction in T1 Gd-enhancing lesions to Week 48, Part B primary: AUC0-W16 and 1 more. Planned start Mar 2025; status: authorised.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-519284-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519284-18-00.